# Catalog # 10-4789
# Binimetinib

CAS# 606143-89-9

6-(4-Bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; ARRY-162

Lot # FBS1125




Binimetinib is a potent ($IC_{50}$ = 12 nM) and selective allosteric inhibitor of MEK1/2.[1,2] Recently approved by the FDA for treatment of melanoma in combination with Encorafenib. Binimetinib has had limited success as monotherapy but has shown promise in combination with other chemotherapeutic agents.[3-5]


1) Lee *et al.* (2010*), Preclinical development of ARRY-162, a potent and selective MEK1/2 inhibitor;* Cancer Res. **70** 2515
2) Winski *et al.* (2010*), MEK162 (ARRY-162), a novel MEK ½ inhibitor, inhibits tumor growth regardless of KRAS/RAF pathway mutations;* EJC Supplements **8** 56
3) Lee *et al.* (2016*), Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models;* Oncotarget **7** 39595
4) Gong *et al.* (2017*), MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines;* Anticancer Res. **37** 2831
5) Van Cutsem *et al.* (2019*), Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From Phase III BEACON Colorectal Cancer study;* J.Clin.Oncol. JCO1802459


## PHYSICAL DATA

| | |
|---|---|
| Molecular Weight: | 441.23 |
| Molecular Formula: | $C_{17}H_{15}BrF_2N_4O_3$ |
| Purity: | >99% by HPLC |
| | NMR: (Conforms) |
| Solubility: | DMSO (>25 mg/ml) |
| Physical Description: | White solid |
| Storage and Stability: | Store as supplied at -20ºC for up to 1 year from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 1 month. |




Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462

www.focusbiomolecules.com